Resonant is a disruptive neurodegenerative disease biotechnology company that develops groundbreaking blood tests that accurately detect and monitor DNA from dying neurons. This DNA serves as biomarkers of neurodegeneration in diseases like Alzheimer’s and may be predictive of neurodegenerative diagnoses before clinical symptoms appear. Resonant is currently conducting a large-scale clinical validation study of its tests for Alzheimer’s, Parkinson’s, and ALS with plans to develop tests for other neurodegenerative conditions such as traumatic brain injury and multiple sclerosis. Visit Our Website

Powered by pioneering technology from leading experts in genetics, epigenetics, and bioinformatics, WBL develops novel technologies for biomarker discovery and targeted, high-throughput clinical use cases. Visit Our Website

Pathogen is a dynamic biotechnology company revolutionizing the detection and monitoring of biomarkers of Lyme and other infectious diseases. With proprietary targeted sequencing technology for identifying and quantifying pathogen-derived DNA directly from blood samples. This technology allows for the early detection of infection biomarkers elusive to conventional methods. With its precise and adaptable approach, Pathogen is well-positioned to develop diagnostic tests for a wide array of infectious diseases.

eXXperts is a pioneering biotechnology company advancing women's health thorugh targeted DNA sequencing technologies. Specializing in the detection of biomarkers for conditions disproportionately affecting women, such as endometriosis and gynecological cancers, eXXperts also develops forensic applications to distinguish menstrual from peripheral blood to aid investigations of crimes against women.